“Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S87. doi:10.25251/skin.2.supp.88.